0.34%
26.83%
2.52%
-6.79%
-40.09%
-58.28%
-46.56%
AI Spotlight on AFX
Company Description
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, the United States, Asia, and internationally.It operates in two segments, Ophthalmic Devices and Microsurgery.The Ophthalmic Devices segment offers products and solutions for the diagnosis and treatment of eye diseases; and systems and consumables for cataract, retinal, and refractive surgeries.
It serves practicing ophthalmologists and optometrists, as well as physicians and surgeons in hospitals and outpatient surgery centers.The Microsurgery segment offers visualization solutions for invasive surgical treatments; and solutions in the area of ear, nose and throat, plastic and reconstructive, dental and spinal surgeries.It serves physicians in various fields and hospitals.
The company was founded in 1846 and is headquartered in Jena, Germany.Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.
Market Data
| Last Price | 59.05 |
| Change Percentage | 0.34% |
| Open | 58.3 |
| Previous Close | 58.85 |
| Market Cap ( Millions) | 5169 |
| Volume | 236207 |
| Year High | 123.75 |
| Year Low | 44.28 |
| M A 50 | 50.86 |
| M A 200 | 65.14 |
Financial Ratios
| FCF Yield | 0.29% |
| Dividend Yield | 1.86% |
| ROE | 8.49% |
| Debt / Equity | 7.41% |
| Net Debt / EBIDTA | 48.01% |
| Price To Book | 2.6 |
| Price Earnings Ratio | 29.65 |
| Price To FCF | 345.41 |
| Price To sales | 2.03 |
| EV / EBITDA | 19.41 |
News
- Jan -13 - ZEISS MEL 90 excimer laser receives U.S. FDA approval; completes Corneal Refractive Workflow
- Dec -31 - An Intrinsic Calculation For Carl Zeiss Meditec AG (ETR:AFX) Suggests It's 41% Undervalued
- Dec -14 - Carl Zeiss Meditec AG Just Beat EPS By 11%: Here's What Analysts Think Will Happen Next
- Dec -13 - Carl Zeiss Meditec Full Year 2024 Earnings: EPS Beats Expectations
- Dec -12 - Carl Zeiss Meditec AG (CZMWF) Q4 2024 Earnings Call Highlights: Navigating Challenges with ...
- Nov -12 - German company Zeiss opens global capability centre in India
- Oct -14 - Is Carl Zeiss Meditec AG's (ETR:AFX) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
- Oct -09 - ZEISS expands ophthalmic offerings to improve patient care with new digital AI tools and revolutionary surgical solutions
- Sep -30 - ZEISS introduces its latest Robotic Visualisation System for neuro surgery
- Sep -30 - What Is Carl Zeiss Meditec AG's (ETR:AFX) Share Price Doing?
- Sep -26 - ZEISS reinvents lens extraction with the first hand-held ultrasound-free lens removal device, available in the U.S.
- Sep -12 - ZEISS Redefines Disease Management and Treatment within the ZEISS Retina Workflow
- Sep -02 - The three-year loss for Carl Zeiss Meditec (ETR:AFX) shareholders likely driven by its shrinking earnings
- Aug -29 - ZEISS innovation paves way to more personalized patient care with cutting-edge AI technology and industry-leading surgical solutions
- Aug -14 - Health Care Roundup: Market Talk
- Aug -14 - Health Care Roundup: Market Talk
- Aug -07 - Private companies account for 59% of Carl Zeiss Meditec AG's (ETR:AFX) ownership, while institutions account for 22%
- Jul -21 - An Intrinsic Calculation For Carl Zeiss Meditec AG (ETR:AFX) Suggests It's 37% Undervalued
- May -30 - ZEISS announces OCT technology enhancements to better support growing era of data-driven patient care
- May -11 - Carl Zeiss Meditec Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Ophthalmology
Expected Growth : 7 %
What the company do ?
Ophthalmology from Carl Zeiss Meditec AG refers to the diagnosis and treatment of eye disorders and diseases using advanced medical technologies and solutions.
Why we expect these perspectives ?
Strong demand for cataract and refractive surgeries, increasing prevalence of eye diseases, and advancements in ophthalmic technologies drive growth in Ophthalmology segment. Zeiss's innovative products, such as SMILE and ReLEx, and strategic partnerships further boost growth. Expanding presence in emerging markets and increasing adoption of digitalization in ophthalmology also contribute to the 7% growth.
Segment n°2 -> Microsurgery
Expected Growth : 9 %
What the company do ?
Microsurgery from Carl Zeiss Meditec AG enables precise and minimally invasive surgical procedures, enhancing visualization and dexterity for optimal patient outcomes.
Why we expect these perspectives ?
Strong demand for minimally invasive procedures, increasing adoption of robotic-assisted microsurgery, and advancements in ophthalmic and neurosurgical applications drive growth. Zeiss' innovative products, such as the ZEISS TIVATO 700, and strategic partnerships expand market share. Growing healthcare expenditure, aging population, and rising prevalence of eye disorders also contribute to the 9% growth.
Carl Zeiss Meditec Ag Products
| Product Range | What is it ? |
|---|---|
| Ophthalmic Diagnostics | Carl Zeiss Meditec AG offers a range of ophthalmic diagnostic systems, including optical coherence tomography (OCT) and ultrasound systems, to help diagnose and monitor eye diseases such as glaucoma, cataracts, and age-related macular degeneration. |
| Intraocular Lenses | The company offers a range of intraocular lenses (IOLs) for cataract surgery, including monofocal, multifocal, and toric lenses, designed to improve visual outcomes and patient satisfaction. |
| Microsurgery Systems | Carl Zeiss Meditec AG provides microsurgery systems for ophthalmic and neurosurgical applications, including vitreoretinal surgery and neurosurgical procedures. |
| Refraction and Imaging Systems | The company offers a range of refraction and imaging systems, including autorefractors, keratometers, and optical coherence tomography (OCT) systems, to support eye care professionals in diagnosing and managing eye diseases. |
| Surgical Ophthalmology | Carl Zeiss Meditec AG provides a range of surgical ophthalmology products, including phacoemulsification systems, vitrectomy systems, and ophthalmic surgical instruments. |
Carl Zeiss Meditec AG's Porter Forces
Threat Of Substitutes
The threat of substitutes for Carl Zeiss Meditec AG is moderate, as there are alternative medical technology companies that offer similar products and services.
Bargaining Power Of Customers
The bargaining power of customers for Carl Zeiss Meditec AG is low, as the company's products and services are specialized and customers have limited alternatives.
Bargaining Power Of Suppliers
The bargaining power of suppliers for Carl Zeiss Meditec AG is moderate, as the company relies on a few key suppliers for critical components and materials.
Threat Of New Entrants
The threat of new entrants for Carl Zeiss Meditec AG is low, as the medical technology industry has high barriers to entry and requires significant capital investment and expertise.
Intensity Of Rivalry
The intensity of rivalry for Carl Zeiss Meditec AG is high, as the medical technology industry is highly competitive and companies must continually innovate and improve their products and services to remain competitive.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 6.73% |
| Debt Cost | 8.59% |
| Equity Weight | 93.27% |
| Equity Cost | 8.59% |
| WACC | 8.59% |
| Leverage | 7.21% |
Carl Zeiss Meditec AG : Quality Control
Carl Zeiss Meditec AG passed 6 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| TECN.SW | Tecan Group AG provides laboratory instruments and solutions for pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. It operates through Life Sciences Business and Partnering Business … |
| YPSN.SW | Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates in two segments, Ypsomed Delivery Systems and … |
| AMP.MI | Amplifon S.p.A. retails hearing care products and services that help people rediscover various emotions of sound. The company offers ampli-easy, ampli-mini, ampli-connect, and ampli-energy hearing devices. It also provides fitting … |
| EKTA-B.ST | Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac … |
| GXI.DE | Gerresheimer AG, together with its subsidiaries, manufactures and sells packaging products, and drug delivery-devices and solutions worldwide. It operates through Plastics & Devices, Primary Packaging Glass, and Advanced Technologies divisions. … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Elekta
A-Score
1-Year Total Return ->
🥈
Ypsomed
A-Score
1-Year Total Return ->
🥉
Amplifon
A-Score
1-Year Total Return ->
4
Tecan
A-Score
1-Year Total Return ->
5
Gerresheimer
A-Score
1-Year Total Return ->
6
